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and Labeling DevelopmentA B S T R A C TWe report a panel designed to open a dialog between pharmaceut-
ical sponsors, regulatory reviewers, and other stakeholders regarding
the use of social media to collect data to support the content
validity of patient-reported outcome instruments in the context
of medical product labeling. Multiple stakeholder perspectives
were brought together to better understand the issues encountered
in pursuing social media as a form of data collection to support
content validity. Presenters represented a pharmaceutical sponsor of
clinical trials, a regulatory reviewer from the Food and Drug
Administration, and an online data platform provider. Each pre-
senter shared its perspective on the advantages and disadvantages
of using social media to collect this type of information. There was
consensus that there is great potential for using social media foree front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.10.001
n@its.jnj.com.
ndence to: Margaret Rothman, Janssen Pharmaceuthis purpose. There remain, however, unanswered questions that
need to be addressed such as identifying which type of social media
is most appropriate for data collection and ensuring that partic-
ipants are representative of the target population while maintaining
the advantages of anonymity provided by online platforms. The use
of social media to collect evidence of content validity holds much
promise. Clariﬁcation of issues that need to be addressed and
accumulation of empirical evidence to address these questions are
essential to moving forward.
Keywords: clinical trials, online communities, patient-reported
outcomes, social media.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Patient-reported outcomes (PROs) are increasingly recognized as
important tools in adding value to the drug review and evalua-
tion process [1] because they provide unique perspectives on
medical conditions or their therapies that are known only to the
patient [2]. “Content validity” describes the extent to which a
PRO intended to assess such subjective outcomes actually
measures the concept of interest [3] and is an ongoing process
that relies on the generation of qualitative and quantitative
evidence. Crucially, PRO measures must reﬂect patient concerns
relative to the concept being assessed and, therefore, documen-
tation of content validity relies on patient input from the target
population of patients [4]. Qualitative studies are used to
generate appropriate items and domains; to ensure the instru-
ment is comprehensive relative to its intended measurement
concept, population, and context of use; and to ensure patient
understanding of the instrument, that is, instructions, items,and response options through cognitive debrieﬁng [5]. Best
practices usually include either individual interviews or focus
groups with participants who are experiencing the target con-
dition or have recent experience with it. These traditional
methods of collecting qualitative data to support the content
validity of a new or existing PRO instrument, however, are labor
intensive, time consuming, and relatively expensive. Although
detailed ﬁgures are not available for speciﬁc parts of the instru-
ment, development estimates from the New England Research
Institutes suggest that developing a PRO from beginning to end
takes at least 24 months and costs between $1 million and $5
million [6], whereas estimates shared at the 2011 C-Path meet-
ing suggest up to 4 years for development and costs between
$725,000 and $2.1 million [7]. Furthermore, there are potential
limitations in the diversity of the sample and the amount of
data that may be collected to support both comprehensiveness
of concepts and understanding of the PRO instrument using
these methodologies [5].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
tical Companies of Johnson & Johnson LLC, Raritan, NJ, USA.
Table 1 – Comparison of traditional methods and
potential for social media in PRO development.
Traditional
methods
Social media
Participant
identiﬁcation
Clinicians, hospital
referral,
advertising
Patient self-
identiﬁcation and
membership of
online
communities
Diagnostic
validation
Primarily
physician or
medical records,
sometimes self-
reported
Primarily self-
reported,
sometimes
electronic medical
records of
physician
Data collection
setting
Face-to-face
individual or
group interviews
Asynchronous
message boards,
instant message
chat, video chat
Data collection
format
Semi-structured
interview, in-
person cognitive
debrieﬁng
Interactive surveys,
questionnaires,
rating scales,
video cognitive
debrieﬁng
Advantages Criterion standard
widely accepted
by researchers
and regulators
as producing
high-quality
outputs
Rapid, cheap,
participatory,
large-scale, new
methods iterate
rapidly. Typed
data do not
require
transcription
Limitations Time and labor
intensive tasks
such as
transcription
and recruitment
New, untested in the
regulatory
approval process
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A new tool that may offer a technological boost to these efforts is
“social media,” a group of Internet-based applications (such as
Facebook, Twitter, forums, or blogs) that allow the creation and
exchange of user-generated content. The Pew Internet & American
Life Project noted in 2011 that the Internet has “changed people’s
relationships with information” in many areas that affect our lives
including health. For example, “online resources, including advice
from peers, are a signiﬁcant source of heath information in the US”
[8]. In a large and nationally representative survey of US adults in
2013, Pew found that 26% of the Internet users had read or
watched someone else’s experience about health or medical issues
in the past year and 16% had tried to ﬁnd others with the same
health concerns, typically through social media [9].
The reach of such online communities is their greatest
strength. For example, it is estimated that in 2013 the number
of total users for the four largest social media platforms was 1.15
billion for Facebook, 500 million for Twitter, 500 million for
Googleþ, and 238 million for LinkedIn (http://visual.ly/social-
media-2013). Given that a proportion of the cost of PRO develop-
ment lies in contacting and recruiting people with speciﬁc
medical conditions and gathering data from them, social media
presents an intriguing new route to accelerating research.
This new form of technology is relatively untested in terms of
the adequacy of the information collected to support current
deﬁnitions of best practices for data generation and analysis. This
is particularly true of research to support content validity for the
development of PROs for use in clinical trials to support labeling
claims in the United States. To capitalize on the advantages of this
new technology, stakeholders need to agree on what is appropriate
methodology and focus research on resolving these issues. Cur-
rently, there is limited knowledge in the public domain on this topic.
To address this question, the authors organized a panel at a
recent ISPOR meeting (2013, New Orleans) to discuss the applica-
tion of social media for this type of data collection. We identiﬁed
four stakeholders to share their perspective although there are
certainly others who may be able to contribute knowledge, exper-
tise, and experience to understanding the topic. Panelists who
contributed to this article included representatives from a phar-
maceutical sponsor of clinical trials (M.R. and A.G.), a US regulatory
reviewer (E.J.P.), and a provider of a patient-powered research
network for data collection through social media (P.W.). Presenters
were asked to share their knowledge and experience, particularly
with respect to their perception of the advantages and disadvan-
tages of using social media to generate data to support the content
validity of PRO measures in the context of drug development
(Table 1). The focus of this panel was on concept elicitation.Beneﬁts of Social Media for PRO Concept Elicitation
All the speakers indicated their belief that there are potential
beneﬁts to using social media for collecting concept elicitation
data. The potential to access larger numbers of persons in the
target population and thus obtain a greater amount of information
in a shorter period of time is an advantage over traditional
methods. Each social network has its own strengths and weak-
nesses (which should be tailored to each study); however, it is
important to recognize that networks go through life cycles far
more rapidly than do traditional social establishments [10].
Although a full review of each network’s strengths and limitations
was outside the scope of the panel, a recent review by Grajales et al.
[11] provides a comprehensive overview of the scientiﬁc literature
describing research with blogs (e.g., Wordpress), microblogs
(e.g., Twitter), social networks (e.g., Facebook), professional sites(e.g., LinkedIn), wikis (e.g., Wikipedia), mashups (e.g., HealthMap),
collaborative ﬁltering sites (e.g., Reddit), media sharing sites (e.g.,
YouTube), and multiuser virtual environments (e.g., Second Life).
In a comparison of semi-structured interviews with blogs for
purposes of PRO development, Acaster and Wild [12] reported a
high degree of convergence about symptoms experienced by
women with menopausal hot ﬂashes, with no major discrepancies
in themes elicited between the two methods. In a study eliciting
concepts among children from ulcerative colitis, Yen et al. [13] used
blogs to substantiate concepts identiﬁed through traditional inter-
views and found these data to be supportive. This area is still
developing, however, and the most recent ISPOR PRO Good
Practices Task Force guidance makes no mention of data gathered
online [14]. It is worth acknowledging, however, that different
forms of social media might have differing potential to offer useful
data. For example, the patient-powered research network Patient-
sLikeMe was recently described in the “tapestry of big data” as
differing from blogs and tweets in that it not only captures
structured data including demographic characteristics, medication,
and diagnoses but also has aspects of a social network [15].
Although the authors are unaware of examples of the use of
social media to develop PRO instruments for regulatory use to
support labeling claims, it is often informative to draw from
examples of uses of social media in instrument development
outside this speciﬁc regulatory context. For instance, among the
potentially broader online population there may be more
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such as those who are too frail to travel or are not located within
reasonable travel distance of a site. In one example provided to
the panel, a long-term patient with amyotrophic lateral sclerosis
(ALS) (who was a psychologist in her working life) complained
that the ALSFRS-R scale [16] had a ﬂoor effect—she had been a
“zero” on this scale for many years. Determined not to be
measured as a zero when there were many things she could still
do, she collaborated with the research team and other patients
with an advanced form of ALS to elicit the things that people who
were nearly “locked in” to their bodies could still do, using the
Internet to survey patients who might be responding using
assistive technology such as eyeblink sensors or tiny switches.
Within just a few weeks, a survey was ﬁelded to over 300 patients
with ALS, including those who had lost their ability to speak as
would be required by traditional research, with subsequent 1-
week and 3-month retests providing additional data, and three
new PRO items were developed for use in those patients in the
most advanced stages of ALS. These ALSFRS-Extension items
have subsequently been translated into other languages [17] and
are used even by the Department of Veteran’s Affairs brain bank
[18], demonstrating a path from patient experience to clinical
research use in a relatively short space of time. Although this
example does not represent a PRO instrument that has under-
gone US regulatory review, it does represent the relevance and
importance of broad patient input and the potential feasibility of
very quickly and efﬁciently assessing the impact of such input on
the psychometric properties of the revised instrument. This also
demonstrates that the use of “social media” is not merely limited
to passive monitoring of otherwise purely social channels such as
Facebook or Twitter [19], which users may feel are not appro-
priate channels for the sharing of medical information [20].
The naturalistic discussions that patients have with one
another online in forums have been used to develop PROs in
other conditions too, such as multiple sclerosis (MS). The MS
Treatment Adherence Questionnaire [21] and the MS Rating Scale
have also been translated into other languages, evaluated against
clinical measurement in the case of the MS Rating Scale [22], and
are being deployed in prospective phase IV studies (e.g., EMD-
Serono’s “Adherence Trial with MS Lifeliness Services,”
NCT01905527). As noted in the ALS example, this PRO instrument
has not undergone US regulatory scrutiny but does offer a model
of some of the advantages that use of social media may bring to
PRO instrument development.
More recently, the Robert Wood Johnson Foundation–funded
“Open Research Exchange” (ORE) has been piloted to allow
researchers from external institutions to develop, iterate upon,
and deploy new PRO measures using volunteers from social media
to develop and provide rapid feedback on PRO items through ﬁve
distinct phases: concept elicitation, feedback, test, retest, and
follow-up [23]. By selecting participants from among a wider pool,
researchers can balance their sample to counteract the biases
inherent in an online platform. Because the marginal resources
needed to recruit 100 participants are not much higher than those
needed to recruit 50 participants, the process can be more efﬁcient
than interviewer-led concept elicitation. For example, the develop-
ment of an Insomnia Impact Questionnaire consisted of a concept
elicitation phase with 16,331 words from 75 patients. This was used
to develop items for a questionnaire that gathered item-level
feedback from 54 selected participants, which yielded qualitative
and quantitative data for improvement to the items. The reﬁned
questionnaire was then ﬁelded to over 1300 patients for a psycho-
metric test phase to establish scale performance. Each phase
(concept elicitation, feedback, and test) took just 7 days. The
software and the engaged population ensure that it is also relatively
straightforward to automate test-retest at different intervals or the
use of different response options with sample sizes adequate forstatistical testing. In a second ORE example, the Treatment Burden
Questionnaire, originally developed in French, underwent an Eng-
lish language pretest in 200 patients from around the world in less
than a month, followed by a 610 patient psychometric test and a
282 patient retest, all in less than 2 months [24]. All PROs developed
on the ORE platform will remain free for anybody to use or build
upon, using Creative Commons licensing arrangements. It is hoped
that this technology can rapidly accelerate and improve upon the
range of PROs available [23].Limitations of Social Media for PRO Concept
Elicitation
Several concerns with using social media to collect concept
elicitation data were noted by the panel. The primary concern
expressed by the panelists related to the uncertainty of the
characteristics of the respondent, extending from demographic
characteristics to diagnosis. In conducting face-to-face interviews
or focus groups, researchers are usually able to seek conﬁrmation
of diagnosis via physician veriﬁcation through a signed waiver
from the patient for access to health information, though this has
the effect of biasing respondents toward those comfortable with
this level of sharing. In contrast, a well-known maxim states that
“On the Internet, nobody knows you’re a dog” [25]. This situation
is changing though as online providers such as MediGuard
undergo similar physician veriﬁcation processes to their ofﬂine
colleagues [26], or increasingly use electronic medical records to
validate that patients are who they say they are [27]. In a concept
elicitation study of 50 patients with chronic lymphocytic leuke-
mia, 80% of the patients agreed that researchers could contact
their physicians to verify their diagnosis [28]. This approach,
however, might have downsides too, in that patients may feel
less comfortable participating or sharing their experiences of
embarrassing or stigmatized conditions, knowing that their
identity will be known and veriﬁed.
Next, it was noted that recruiting the right patients is
important regardless of the platform. For the development of
instruments intended for use in medical product development,
the respondents should adequately represent the targeted clin-
ical trial population because content validity is context speciﬁc.
In uncommon conditions such as organ transplantation, social
media can have a wide reach; as many as 1% of all those
receiving an organ transplant in 2009 shared their medical data
on PatientsLikeMe [29], and Facebook was recently used to
identify pediatric transplant patients who had been lost to
follow-up by a clinical center [30]. Participants in social media
currently tend to be biased, however, toward younger patients,
those who are female, or those with higher levels of education
relative to clinical populations [1]. With a sufﬁciently large
sample, this issue can be addressed, however, by taking a
stratiﬁed sampling approach in the recruitment phase.
Another concern related to the deﬁnition of social media, in
that there are different types of digital media that may be used
for collecting qualitative data. For instance, contacting patients
who have volunteered to participate in a medical community
associated with research (such as Genomera or 23andMe) is
different from attempting to recruit people through Facebook
who might not be expecting to be targeted on the basis of their
proﬁle data or medical charity pages they have “liked.” Some
forms of social media such as Twitter are inherently limited to
brief (140 character) communications, and it is unclear to what
extent the abbreviated and asynchronous nature of online com-
munication will hold up to the nuanced probing of a trained
qualitative interviewer. Branthwaite and Pattterson [19] suggest
that social media fails to capitalize on the distinguishing features
of qualitative research: having a conversation (rather than an
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moment), active listening (rather than a software textbox unable
to probe the “space between words”), and an interactive “merging
of minds” or “rapport” (rather than an audience of “followers”).
Research will be needed to map out the advantages and dis-
advantages of each type of social media so that they may be more
clearly understood moving forward, and if social media is going
to have a place in the researchers toolkit, it is possible that these
systems will adapt to overcome the limitations identiﬁed.Conclusions
Overall, the panelists indicated that social media holds great
potential as a means of recruitment of patients for qualitative
research and collecting data to support the content validity of
PRO measures used in product labeling as long as best practices
are applied. The efforts of professional bodies such as ISPOR to
embrace and validate other newer digital techniques such as e-
PRO [1] provide reassurance that research required to advance
our understanding can be achieved. Speciﬁc concerns that need
to be addressed include ways to have more conﬁdence in the
characteristics of the participant, especially diagnostic criteria,
and more research is needed to understand the speciﬁc strengths
and weaknesses of different forms of social media. It may be the
case that a mixture of both face-to-face and online data collection
offers advantages over either methodology alone.
Source of ﬁnancial support: The authors have no other
ﬁnancial relationships to disclose.
R E F E R E N C E S[1] Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s
perspective into drug development and communication: an ad hoc task
force report of the Patient-Reported Outcomes (PRO) Harmonization
Group meeting at the Food and Drug Administration, February 16, 2001.
Value Health 2003;6:522–31.
[2] Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to
support medical product labeling claims: FDA perspective. Value Health
2007;10(Suppl):S125–37.
[3] Fayers P, Machin D. Quality of Life: The Assessment. Analysis and
Interpretation of Patient-Reported Outcomes 2007.
[4] U.S. Department of Health and Human Services, Food and Drug
Administration. Guidance for industry: patient-reported outcome
measures—use in medical product development to support labeling
claims. Fed Reg 2009;74:65132–3.
[5] Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported
outcome (PRO) instruments and their modiﬁcation: the ISPOR Good
Research Practices for Evaluating and Documenting Content Validity
for the Use of Existing Instruments and Their Modiﬁcation PRO Task
Force Report. Value Health 2009;12:1075–83.
[6] Rosen R. Development of patient reported outcome (PRO) measures:
how feasible is a PRO for asymptomatic PCa treatment? In: FDA Public
Workshop: Clinical Trial Design Issues—Drug and Device Development
for Localized Prostate Cancer; San Diego, CA; May 5, 2013.
[7] Hayes R. Patient-reported outcome (PRO) instruments as drug
development tools (session III). In: Consensus Science: New Tools and
Tactics for Next-Gen Drug Development. Washington, DC; 2011.
[8] Fox S. The social life of health information. Pew Research Center’s Internet
& American Life Project. Washington, DC: Pew Research Center, 2011.[9] Fox S, Duggan M. Health online 2013. Available from: http://www.
pewinternet.org/2013/01/15/health-online-2013/.
[10] Young C. Community management that works: how to build and
sustain a thriving online health community. J Med Internet Res 2013;15:
e119.
[11] Grajales FJ, Sheps S, Ho K, et al. Social media: a review and tutorial of
applications in medicine and health care. J Med Internet Res 2014;16:
e13.
[12] Acaster SL, Wild D. PMC65: a novel comparison of qualitative data
sources: content analysis of semi-structured patient interviews versus
weblogs (Blogs). Value Health 2009;12:A31.
[13] Yen L, Flood E, Beusterien K, et al. PGI25—development of patient-
reported outcomes (Pro) and observer-reported outcomes (Obsro)
measures for pediatric ulcerative colitis: concept elicitation ﬁndings.
Value Health 2013;16:A216.
[14] Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity—establishing
and reporting the evidence in newly developed patient-reported
outcomes (PRO) instruments for medical product evaluation:
ISPOR PRO Good Research Practices Task Force report: part 1—eliciting
concepts for a new PRO instrument. Value Health 2011;14:967–77.
[15] Weber GM, Mandl KD, Kohane IS. Finding the missing link for big
biomedical data. JAMA 2014;311:2479–80.
[16] Cedarbaum JM, Stambler N, Malta E, Fuller C. The ALSFRS-R: a revised
ALS functional rating scale that incorporates assessments of
respiratory function. J Neurol Sci 1999;169:13–21.
[17] Abdulla S, Vielhaber S, Körner S, et al. Validation of the German version
of the extended ALS functional rating scale as a patient-reported
outcome measure. J Neurol 2013;260:2242–55.
[18] Brady CB, Trevor KT, Stein TD, et al. The Department of Veterans
Affairs Biorepository Brain Bank: a national resource for amyotrophic
lateral sclerosis research. Amyotroph Lateral Scler Frontotemporal
Degener 2013;14:591–7.
[19] Branthwaite A, Patterson S. The power of qualitative research in the era
of social media. Qual Market Res 2011;14:430–40.
[20] van der Velden M, El Emam K. “Not all my friends need to know”: a
qualitative study of teenage patients, privacy, and social media. J Am
Med Inform Assoc 2013;20:16–24.
[21] Wicks P, Massagli M, Kulkarni A, Dastani H. Use of an online
community to develop patient-reported outcome instruments: the
Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).
J Med Internet Res 2011;13:e12.
[22] Bove R, Secor E, Healy BC, et al. Evaluation of an online platform for
multiple sclerosis research: patient description, validation of severity
scale, and exploration of BMI effects on disease course. PLoS One
2013;8:e59707.
[23] Wicks P, Heywood B, Heywood J. Online platform to accelerate patient
involvement in open instrument development. Qual Life Res
2013;22:55.
[24] Tran V-T, Harrington M, Montori VM, et al. Adaptation and validation
of the Treatment Burden Questionnaire (TBQ) in English using an
internet platform. BMC Med 2014;12:109.
[25] Steiner P. On the Internet, nobody knows you’re a dog. New Yorker
1993;69:61.
[26] Cascade E, Ford D, Nixon M, et al. PCV124 Combining electronic health
records and patient-reported information in the UK: preliminary
results from wasps (Wales Sail þ Pro Study). Value Health 2012;15:
A134–5.
[27] Cascade E, Marr P, Winslow M, Tuttle D. PMS94 Integrating patient-
reported outcomes (PRO) and medical record data (MR) in observational
study designs: results from a direct-to-patient pilot study in gout. Value
Health 2012;15: A51–A51.
[28] McCarrier KP, Bull S, Simacek KF, et al. Online social networks-based
qualitative research to identify patient-relevant concepts in chronic
lymphocytic leukemia. Value Health 2014;17:A196.
[29] Wicks P, Sulham KA, Gnanasakthy A. Quality of life in organ transplant
recipients participating in an online transplant community. Patient
2014;7:73–84.
[30] Mohammad S, Hormaza L, Neighbors K, et al. Health status in young
adults two decades after pediatric liver transplantation. Am J
Transplant 2012;12:1486–95.
